Although the market for molecular diagnostics is fragmented with more than 500 companies, the most prominent players are Roche Diagnostics (Switzerland), Novartis (Switzerland), Gen-Probe (U.S.), Qiagen (The Netherlands), Abbott Diagnostics (U.S.), Becton
(PRWEB) January 04, 2013
The new market research report “Molecular Diagnostics Market - Technologies (PCR, DNA Sequencing, Microarray, Spectroscopy), Applications (Virology/Infectious Diseases, Cancer/Oncology, Genetic Testing) - Global Opportunities, Competitor Analysis & Forecasts to 2017” analyzes and studies the major market drivers, restraints, and opportunities in North America, Europe, Asia, and Rest of the World.
Browse 130+ market data tables/ figures spread through 391 pages and in-depth TOC of “Molecular Diagnostics Market - Technologies, Applications - Global Opportunities, Competitor Analysis & Forecasts to 2017”.
Early buyers will receive 10% customization on reports.
This report studies the global molecular diagnostics market, with forecast to 2017.
Molecular Diagnostics Market (MDx) is a new class of diagnostic tests that identify nucleic acids or proteins to test the status of a disease. These nucleic acids or proteins, which belong to individual patients or foreign organisms, help determine a specific therapy, or risk of developing a specific disease, or other health conditions. MDx is the fastest growing segment within the in-vitro diagnostic (IVD) space, driven by accuracy, high sensitivity, fast turnaround time, easy workflow, and cost-effective testing. Owing to these factors, the molecular diagnostics market crossed $4.8 billion in 2011, and is poised to grow at a CAGR of 9.1% in the next five years to reach $8.1 billion.
Molecular diagnostics has applications in infectious disease molecular testing, oncology, blood screening, genetic testing, DNA fingerprinting (e.g., paternity testing, forensic testing), microbiology, tissue typing, and food pathogen detection testing. The booming MDx areas are molecular tests for women’s health, oncology, and organ transplant testing.
Factors like increase in awareness and acceptance of personalized medicine, advancements in molecular techniques, and increasing investments in proteomics and genomics research will spur the molecular diagnostics market in the future. Yet, reimbursement issues for non-coded tests and complex regulatory framework will restrict the growth of this market.
Although the market for molecular diagnostics is fragmented with more than 500 companies, the most prominent players are Roche Diagnostics (Switzerland), Novartis (Switzerland), Gen-Probe (U.S.), Qiagen (The Netherlands), Abbott Diagnostics (U.S.), Becton Dickinson (U.S.) and Cepheid (U.S.), to name a few.
MarketsandMarkets is a global market research and consulting company based in the U.S. We publish strategically analyzed market research reports and serve as a business intelligence partner to Fortune 500 companies across the world.
MarketsandMarkets also provides multi-client reports, company profiles, databases, and custom research services. They cover thirteen industry verticals, including advanced materials, automotives and transportation, banking and financial services, biotechnology, chemicals, consumer goods, energy and power, food and beverages, industrial automation, medical devices, pharmaceuticals, semiconductor and electronics, and telecommunications and IT.
We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository. To know more about us and our reports, please visit our website http://www.marketsandmarkets.com
North - Dominion Plaza,
17304 Preston Road,
Suite 800, Dallas, TX 75252